Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Journal of Clinical Oncology

Volumn 32, Issue 11, 2014, Pages 1157-1163

  Ogura, Michinori ^a   Ishida, Takashi ^b   Inagaki, Hiroshi ^b   Yamamoto, Kazuhito ^c   Ueda, Ryuzo ^d   Hatake, Kiyohiko ^e   Tobinai, Kensei ^f   Akinaga, Shiro ^g   Taniwaki, Masafumi ^h   Ando, Kiyoshi ⁱ   Fujimoto, Katsuya ^j   Miyamoto, Toshihiro ^k   Uike, Naokuni ^l   Tamura, Kazuo ^m   Tanimoto, Mitsune ⁿ   Tsukasaki, Kunihiro ^o   Tomonaga, Masao ^p   Ishizawa, Kenichi ^q   Suzumiya, Junji ^r  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e CANCER CHEMOTHERAPY CENTER   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g KYOWA HAKKO KOGYO CO LTD   (Japan)

^h KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

ⁱ TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k KYUSHU UNIVERSITY   (Japan)

^l NATIONAL KYUSHU CANCER CENTER   (Japan)

^m FUKUOKA UNIVERSITY   (Japan)

ⁿ OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^o NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^p Japanese Red Cross Nagasaki Atomic Bomb Hospital Nagasaki   (Japan)

^q TOHOKU UNIVERSITY HOSPITAL   (Japan)

^r SHIMANE UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HYDROCORTISONE; MOGAMULIZUMAB; CHEMOKINE RECEPTOR CCR4; MONOCLONAL ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLS; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; CUTANEOUS T CELL LYMPHOMA; CYTOMEGALOVIRUS RETINITIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HERPES SIMPLEX; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFUSION RELATED REACTION; LEUKEMIA RELAPSE; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POLYMYOSITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PSORIASIS VULGARIS; SECOND CANCER; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; THRUSH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; DRUG ANTAGONISM; IMMUNOLOGY; JAPAN; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; JAPAN; LYMPHOMA, T-CELL, CUTANEOUS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, CCR4; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84901432982     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.0924     Document Type: Article

References (41)

1. WHO: WHO classification of tumours of haematopoietic and lymphoid tissues (ed 4). Lyon, France, International Agency for Research on Cancer (IARC), 2008
2. O'Leary HM, Savage KJ: Update on the World Health Organization classification of peripheral T-cell lymphomas. Curr Hematol Malig Rep 4:227-235, 2009
3. Vose J, Armitage J, Weisenburger D, et al: International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008
4. Lymphoma Study Group of Japanese Pathologists: The World Health Organization classification of malignant lymphomas in Japan: Incidence of recently recognized entities. Pathol Int 50:696-702, 2000
5. Aoki R, Karube K, Sugita Y, et al: Distribution of malignant lymphoma in Japan: Analysis of 2260 cases, 2001-2006. Pathol Int 58:174-182, 2008 (Pubitemid 351190172)
6. Wollina U: Cutaneous T cell lymphoma: Update on treatment. Int J Dermatol 51:1019-1036, 2012
7. NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin's lymphomas. Version 1.2013. Fort Washington, PA, NCCN Clinical Practice Guidelines in Oncology, 2013
8. Savage KJ, Chhanabhai M, Gascoyne RD, et al: Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15:1467-1475, 2004 (Pubitemid 39409735)
9. Savage KJ: Therapies for peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2011:515-524, 2011
10. O'Connor OA, Pro B, Pinter-Brown L, et al: Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. J Clin Oncol 29:1182-1189, 2011
11. Coiffier B, Pro B, Prince HM, et al: Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30:631-636, 2012
12. Pro B, Advani R, Brice P, et al: Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J Clin Oncol 30:2190-2196, 2012
13. Sugaya M, Hamada T, Kawai K, et al: Guidelines for the management of cutaneous lymphomas (2011): A consensus statement by the Japanese Skin Cancer Society-Lymphoma Study Group. J Dermatol 40:2-14, 2013
14. Olsen E, Vonderheid E, Pimpinelli N, et al: Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:1713-1722, 2007 (Pubitemid 47443880)
15. Kim YH, Liu HL, Mraz-Gernhard S, et al: Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome. Clinical prognostic factors and risk for disease progression. Arch Dermatol 139:857-866, 2003 (Pubitemid 36898920)
16. Diamandidou E, Colome-Grimmer M, Fayad L, et al: Transformation of mycosis fungoides/Sezary syndrome: Clinical characteristics and prognosis. Blood 92:1150-1159, 1998 (Pubitemid 28369027)
17. Olsen EA, Kim YH, Kuzel TM, et al: Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109-3115, 2007 (Pubitemid 47218059)
18. Olsen E, Duvic M, Frankel A, et al: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376-388, 2001 (Pubitemid 32112849)
19. Whittaker SJ, Demierre MF, Kim EJ, et al: Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28:4485-4491, 2010
20. Jones D, O'Hara C, Kraus MD, et al: Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 96:685-690, 2000 (Pubitemid 30463392)
21. Ishida T, Inagaki H, Utsunomiya A, et al: CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 10:5494-5500, 2004 (Pubitemid 39100487)
22. Ohshima K, Karube K, Kawano R, et al: Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis. Int J Oncol 25:605-613, 2004
23. Nakagawa M, Nakagawa-Oshiro A, Karnan S, et al: Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia/lymphoma. Clin Cancer Res 15:30-38, 2009
24. Yagi H, Seo N, Ohshima A, et al: Chemokine receptor expression in cutaneous T cell and NK/Tcell lymphomas: Immunohistochemical staining and in vitro chemotactic assay. Am J Surg Pathol 30:1111-1119, 2006 (Pubitemid 44299344)
25. Shinkawa T, Nakamura K, Yamane N, et al: The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278:3466-3473, 2003 (Pubitemid 36801263)
26. Niwa R, Sakurada M, Kobayashi Y, et al: Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 11:2327-2336, 2005 (Pubitemid 40490194)
27. Niwa R, Shoji-Hosaka E, Sakurada M, et al: Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 64:2127-2133, 2004 (Pubitemid 38339463)
28. Yano H, Ishida T, Inagaki A, et al: Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: A novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. Clin Cancer Res 13:6494-6500, 2007 (Pubitemid 350075040)
29. Yamamoto K, Utsunomiya A, Tobinai K, et al: Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28:1591-1598, 2010
30. Ishida T, Joh T, Uike N, et al: Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. J Clin Oncol 10:837-842, 2012
31. Duvic M, Pinter-Brown L, Foss F, et al: Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. Presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego, CA, December 10-13, 2011 (abstr 962)
32. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253, 1999 (Pubitemid 29162950)
33. Tsukasaki K, Hermine O, Bazarbachi A, et al: Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting. J Clin Oncol 27:453-459, 2009
34. Stevens SR, Ke MS, Parry EJ, et al: Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: The severity-weighted assessment tool (SWAT). Arch Dermatol 138:42-48, 2002 (Pubitemid 34056233)
35. Olsen EA, Whittaker S, Kim YH, et al: Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 29:2598-2607, 2011
36. Ishida T, Ueda R: CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 97:1139-1146, 2006 (Pubitemid 44430638)
37. d'Amore F, Radford J, Relander T, et al: Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol 150:565-573, 2010
38. Hodi FS, O'Day JS, McDermott FD, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
39. Campbell JJ, Haraldsen G, Pan J, et al: The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 400:776-780, 1999 (Pubitemid 29399540)
40. Ishida T, Ito A, Sato F, et al: Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 104:647-650, 2013
41. Lunning MA, Gonsky J, Ruan J, et al: Pralatrexate in relapsed/refractory HTLV-1 associated adult T-cell lymphoma/leukemia: A New York City multi-institutional experience. Blood 120 (ASH Annual Meeting). 2012 (abstr 2735)